[Preventive effect of dipropylacetamide in bipolar manic-depressive psychoses].
Dipropylacetamide (DEPAMIDE) was administered to 60 patients with bipolar manic-depressive psychoses. The dosage was 900 mg per day, administered orally. In 5 (8%) of the patients gastrointestinal disorders were observed. Administration of lithium carbonate results in undesirable side-effects in 50% of the cases. Our clinical experience shows dipropylacetamide to have a considerably slighter toxic effect on the human organism than lithium carbonate. We regard Dipropylacetamide (DEPAMIDE) as a valuable and significant addition in the prophylaxis of affective disorders, notably bipolar manic-depressive psychoses.
D000927:Anticonvulsants / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000517:prevention & control*; D006801:Humans; D014635:Valproic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000927:Anticonvulsants; D014635:Valproic Acid; C004651:dipropylacetamide
Die prophylaktische Wirkung von Dipropylazetamid bei bipolaren manisch-depressiven Psychosen.